Additive Manufacturing Strategies

Prellis Biologics Secures $14.5M for Bioprinted Lymph Node

ST Medical Devices

Share this Article

Prellis Biologics secured a $14.5 million series B round lead by Celesta Capital with existing shareholders Khosla Ventures. Prellis has an Externalized Immune System (EXIS) platform which allows researchers to discover antibodies by mimicking the lymph node. The company claims that this will reduce the time to discover new antibodies from nine months to just 16 days. The platform allows the firm to reduce animal testing and discover antibodies to combat disease. Prellis is exciting because it can enhance and accelerate drug discovery and potentially reduce animal testing drastically.

The company says that the EXIS platform “functions precisely like a human lymph node“, in that it features cell-to-cell interactions within tissues and immune responses, as well as “B cell class switching, somatic hypermutation and development of antigen-specific human antibodies from multiple donors.” Additionally, the company claims to use “an antigen challenge carefully designed to ‘break tolerance’ a naturally embedded fail-safe that prevents auto-antibody development.” In turn, EXIS is able to be leveraged for developing antibodies across a number of therapeutic applications, from cancer to autoimmune disease, as well as “camelid nanobody discovery.”

“The EXIS platform offers unprecedented in vitro access to a functional human immune system. We’ve built a platform that enables promising science to be rapidly advanced into new patient therapies. We’re thrilled to continue expanding upon the exciting potential of this technology, thanks to the support of our investors and collaboration partners,” said CEO Dr. Melanie P. Matheu.

“We are extremely excited about the technology Prellis has developed and were delighted to support this investment. Today, pharmaceutical antibody discovery takes a long time, carries high costs due to reliance on animals, and the antibodies too rarely perform as hoped once they reach human trials. We are ready to support marketing for the EXIS platform now that initial deals have helped to prove out its great potential,” contributed Michael Marks, General Partner at Celesta Capital.

The company has hired Kevin Chapman from Merck & Co., Inc., as Chief Scientific Officer and Yelda Kaya as Chief Business Officer to help it expand. In addition to EXIS, the company also develops 3D tissue models. The firm has raised just under $30 million so far for its groundbreaking technology.

The stated goal of Prellis is to develop printable organs for implantation. This is a complex and difficult challenge to undertake, but the reason I’m very excited about this firm is that they have a very good shot at a very powerful intermediate business model, as well. Later on, the team could market tissues that might be advantageous.

For now, however, their own tooling in the form of EXIS could have significant effects. EXIS could aid the company’s own path toward achieving its goal, but it could also help the team find very many interesting compounds that it could license, bring to market with partners, or develop into drugs. If it manages to do this in a capital-light manner for itself, it would be able to give away less equity to investors. Instead of needing an endless stream of investor cash, it could license its relevant antibodies to generate funds, giving it the wherewithal to increase its capabilities.

If EXIS works as advertised the firm would be worth a lot to the pharmaceutical industry without getting any closer to printing tissue through its ability to accelerate drug development. I love that this is a startup with a lot of options and a lot of exits. There is a big goal and opportunity at the end of the tunnel, but even if the firm does not reach this big goal it will still deliver on a lot of potential value for shareholders and the market in general. This seems like a very smart play.

Share this Article


Recent News

Carbon’s Next Gen 3D Printers Smoother and Faster with 4K Light Engine

Quantum Computing Boosted by Nanoscribe’s New Microscale 3D Printer



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Photocentric Expands with New 3D Printer, Materials, and Partnerships

Photocentric is the inventor of, and leader in, 3D printing based on LCD screen technology. Based in Cambridgeshire, UK and Arizona, US, the company has a patent in visible light...

Featured

Electronics 3D Printing: Analysis of Rogers Corp’s New Dielectric Material for AM

Rogers Corporation (NYSE:ROG) has launched its Radix 3D Printable Dielectrics series of products at the IPC APEX EXPO 2022 currently taking place in San Diego. The materials signify an important...

To End Animal Testing, BICO & CCS Push FDA Modernization Act

As the world continues developing alternatives to animal testing like bioprinting, in vitro models of human tissues, and predictive computer models, the demand for live animal testing has become outdated...

$2M in Electronics 3D Printers Sold to Military Customer by Optomec

While we’re still not able to 3D print an entire iPhone at once, electronics 3D printing may be progressing more quickly than most people might notice. A pioneer in this...


Shop

View our broad assortment of in house and third party products.